Physician profile
Sarah E Casper
NPI 1982727178
$1,525.07
in general payments reported to CMS, 2019-2025
28 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $329 · 2022: $228 · 2023: $292 · 2024: $267 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.70 | 2021-2025 | |
| Pfizer INC. | $158.71 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $141.65 | 2021-2024 | Breztri, Farxiga |
| Novo Nordisk INC | $127.22 | 2021-2025 | Wegovy, Saxenda |
| Amgen INC. | $107.86 | 2022-2025 | Evenity, Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $100.01 | 2025 | Recorlev |
| Lilly USA, LLC | $65.30 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Alexion Pharmaceuticals, INC. | $44.15 | 2021-2022 | |
| Amarin Pharma, INC. | $43.79 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.74 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $42.16 | 2023-2025 | Spravato |
| Axsome Therapeutics, INC. | $41.82 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $34.88 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $34.31 | 2024-2025 | Cologuard Collection Kit |
| Seqirus USA INC | $32.74 | 2022-2024 | Fluad, Flucelvax |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $31.30 | 2023 | Inspire |
| Nevro Corp. | $28.33 | 2021 | |
| Lundbeck LLC | $22.36 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $21.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.30 | 2022 | |
| Medtronic, INC. | $20.27 | 2025 | Inceptiv |
| Abbott Laboratories | $19.45 | 2024 | Alere Cholestech Ldx |
| Sanofi Pasteur INC. | $19.42 | 2022 | |
| Glaxosmithkline, LLC. | $17.55 | 2023 | Shingrix, Arexvy |
| Avanir Pharmaceuticals, INC. | $16.09 | 2021 | |
| Cranial Technologies, INC | $14.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.06 | 2022 | |
| Merck Sharp & Dohme LLC | $13.43 | 2024 | Gardasil 9, Vaxneuvance, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Casper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.